Moderna (NASDAQ:MRNA) Lowered to “Equal Weight” Rating by Barclays

Barclays downgraded shares of Moderna (NASDAQ:MRNA) from an overweight rating to an equal weight rating in a report published on Tuesday, MarketBeat reports. They currently have $45.00 price target on the stock, down from their previous price target of $111.00.

Other equities research analysts have also recently issued reports about the company. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Wolfe Research assumed coverage on shares of Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Berenberg Bank lifted their price target on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Finally, Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus price target of $61.58.

Moderna Stock Performance

NASDAQ MRNA opened at $35.72 on Tuesday. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna has a twelve month low of $29.25 and a twelve month high of $170.47. The stock has a fifty day simple moving average of $38.61 and a 200 day simple moving average of $53.82. The company has a market capitalization of $13.75 billion, a price-to-earnings ratio of -6.14 and a beta of 1.59.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 2,664 shares of company stock valued at $115,210 in the last three months. 15.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

A number of hedge funds have recently made changes to their positions in MRNA. Intrinsic Value Partners LLC raised its position in shares of Moderna by 91.1% in the 3rd quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after purchasing an additional 24,505 shares in the last quarter. Banco Santander S.A. acquired a new position in shares of Moderna during the third quarter valued at approximately $3,550,000. John G Ullman & Associates Inc. lifted its holdings in shares of Moderna by 341.3% in the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after buying an additional 38,400 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Moderna by 11.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after buying an additional 167,596 shares in the last quarter. Finally, abrdn plc raised its holdings in Moderna by 28.1% during the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock worth $12,842,000 after buying an additional 69,360 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.